Over the past months, Oximio has continued to strengthen its foundation in the United Kingdom – a region that plays a vital role in our global clinical trial supply chain.
A recent, successful, independent audit in the UK reaffirmed not only our financial health but also our commitment to transparency, compliance, and operational excellence.
Dr Zayheda Khan, Chief Commercial Officer & Managing Director (UK), said “Establishing solid roots in such a highly regulated and competitive environment allows us to better support clinical trials across Europe and beyond. It’s a reflection of the dedication of our teams, our partners’ trust, and our ongoing focus on doing things the right way – ethically, sustainably, and reliably”.
As we move forward, our focus remains clear: developing stronger relationships, and a resilient global foundation that enables scalable, future-ready clinical trial solutions.